Saxenda for obesity

How Saxenda (liraglutide) is used in obesity, what the clinical evidence shows, and how it compares to other treatment options.

Off-label useNot FDA-approved for obesity — used off-label based on clinical judgment

Obesity: what it is

Obesity is a chronic disease defined by excess body fat that increases the risk of cardiovascular disease, type 2 diabetes, and other comorbidities. The American Medical Association recognized obesity as a disease in 2013. Standard threshold: BMI ≥30 (or ≥27 with a weight-related condition).

How Saxenda fits into obesity treatment

First-line: lifestyle modification (calorie deficit, structured physical activity, behavioral counseling). Pharmacotherapy is indicated for BMI ≥30 or ≥27 with comorbidity. GLP-1 receptor agonists (semaglutide/Wegovy, liraglutide/Saxenda) and the dual GLP-1/GIP agonist tirzepatide (Zepbound) are now first-line drug therapy due to 14-22% mean body-weight reduction in trials. Older agents (phentermine, naltrexone-bupropion, orlistat) remain options. Bariatric surgery for BMI ≥40 or ≥35 with severe comorbidity.

Saxenda works by: Single GLP-1 receptor agonist. Same mechanism family as semaglutide/Wegovy but shorter half-life (~13 hours) requiring daily dosing instead of weekly.

Who qualifies for Saxenda for obesity

FDA indication: adults BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. Adolescents 12+ with body weight >60 kg also approved. Insurance coverage often requires step therapy from older anti-obesity drugs.

Off-label note: Saxenda is not FDA-approved for obesity. Off-label prescribing is legal and clinically appropriate when supported by evidence and shared clinical decision-making. Insurance coverage for off-label use is often more difficult than for labeled indications — expect prior-authorization challenges and stronger documentation requirements.

Clinical evidence

8.4% mean body-weight reduction at 56 weeks (3.0 mg dose)

Trial: SCALE Obesity & Prediabetes (NCT01272219) · vs 2.8% with placebo · N = 3,731

How Saxenda compares to other obesity treatments

Frequently asked about obesity

Is obesity considered a disease?: Yes. The American Medical Association formally recognized obesity as a disease in 2013, and the World Health Organization classifies it as a chronic condition. This framing matters clinically (it justifies long-term treatment) and financially (it supports insurance coverage of pharmacotherapy).
How much weight loss is clinically meaningful?: 5-10% body-weight reduction sustained for 6+ months produces measurable improvement in blood pressure, lipids, glucose control, and quality of life. GLP-1 trials produce 14-22% mean weight loss — well above the threshold for clinical benefit.
Do I need to fail diet and exercise before getting a GLP-1?: Clinical guidelines no longer require documented failure of lifestyle intervention before initiating pharmacotherapy if BMI criteria are met. Many insurance plans, however, do require documented prior attempts. A program with an insurance concierge handles this paperwork for you.
Will I have to take a GLP-1 forever?: Trial extension data shows roughly two-thirds of lost weight returns within 12-18 months of discontinuation. The clinical model is chronic-disease treatment, similar to managing hypertension or hyperlipidemia. Some patients move to a lower maintenance dose rather than a full stop.

Saxenda for other conditions

Saxenda is only catalogued for obesity in our condition library.